|
Hemodynamic Safety Markers |
||||||||||
| 300 mg |
600 mg |
|||||||||
|
|
||||||||||
| Week |
0 |
1 |
3 |
8 |
11 |
0 |
1 |
3 |
8 |
11 |
|
|
||||||||||
| Heart Rate (bpm) |
64 ± 7.6 |
58 ± 4.7 |
61 ± 5.1 |
61 ± 5.6 |
64 ± 8.7 |
57 ± 6.2 |
58 ± 6.7 |
59 ± 7.2 |
61 ± 3.0 |
64 ± 8.6 |
| SBP (mmHg) |
116 ± 13.0* |
114 ± 9.8* |
117 ± 12.3* |
117 ± 10.7* |
116 ± 8.8* |
75 ± 8.7 |
74 ± 9.3 |
73 ± 8.1 |
70 ± 7.9 |
77 ± 5.6 |
| BBP (mmHg) |
109 ± 6.4 |
107 ± 5.2 |
113 ± 6.9 |
115 ± 11.4 |
114 ± 4.8 |
69 ± 8.2 |
74 ± 4.5 |
71 ± 9.4 |
76 ± 9.9 |
74 ± 6.3 |
|
* Denotes significant main effects for groups (p < 0.05). Results indicated that the 300 mg group had significant higher baseline values that persisted throughout the study, and was apparently independent of 6-OXO supplementation. | ||||||||||
Rohle et al. Journal of the International Society of Sports Nutrition 2007 4:13 doi:10.1186/1550-2783-4-13 |
||||||||||